Skip to main content
main-content

2020 Genitourinary Cancers Symposium coverage

NEWS AND EXPERT INTERVIEWS FROM THE MEETING (FEBRUARY 13–15, 2020).

Expert interviews

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The ATLAS trial

Petros Grivas explains why the story of PARP inhibitors in advanced urothelial carcinoma is not quite finished yet despite the negative results of the ATLAS trial of rucaparib in this setting (4:45).

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The COSMIC-021 mCRPC cohort

Neeraj Agarwal outlines the findings of the metastatic castration-resistant prostate cancer cohort of the COSMIC-021 trial of cabozantinib plus atezolizumab (3:21).

Read the accompanying news story

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Sitravatinib plus nivolumab in advanced RCC

Pavlos Msaouel reports on the efficacy and toxicity of combined treatment with the novel tyrosine kinase inhibitor sitravatinib and nivolumab in people with advanced renal cell carcinoma (4:53).

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert highlights from ASCO GU 2020

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert comment: Novel agents in advanced RCC

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The BLASST-1 trial

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The RADVAX RCC study

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: HIF-2α inhibition in RCC

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert comment: The CARD, TITAN, and STOMP trials

Expert discussion

Treatment options for advanced RCC: Updates from ASCO GU 2020

Axel Merseburger and Laurence Albigès discuss the treatment options for patients with RCC and highlight some of the novel data presented at the 2020 Genitourinary Cancers Symposium that may affect practice in the future.

Metastatic RCC updates from ASCO GU 2020

Bernard Escudier and Viktor Grünwald take us through the studies that caught their attention at the 2020 Genitourinary Cancers Symposium, including long-term data from the CheckMate 214 trial and studies of novel agents such as the HIF-2α inhibitor MK-6482 and sitravatinib.

Research news

Reference

2020 Genitourinary Cancers Symposium key clinical trials

Read concise summaries of the practice-changing clinical trials being presented at ASCO GU 2020. Highlights include the CHHiP, NIVES, NIMBUS, KEYNOTE-199 and RADVAX RCC trials.


Medicine Matters conference coverage is brought to you in partnership with medwireNews



Image Credits